What Is Prestige Consumer Healthcare In (PBH) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Prestige Consumer Healthcare In presents a highly debated valuation profile at its current price of $47.19. The composite intrinsic value is estimated at $46.43 (-1.6% average upside), masking a wide model spread between the 5 bullish models and 5 bearish models. Model dispersion is worth noting: RCMH-DCF targets $93.65 (+98.5%), versus Markov DDM at $9.17 (-80.6%). This +179.0% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, Bayesian DCF, EPV, EROIC lean bearish — adding weight to the bearish side of the thesis.
What Do the Models Say About PBH?
12 of 13 models are currently active for PBH. Of these, 6 models suggest upside while 6 models suggest overvaluation. The Bayesian DCF estimates PBH's intrinsic value at $63.10, implying +33.7% upside from the current price. See which stocks rank higher →
How Does PBH Rank in Pharmaceutical Preparations?
Among 469 Pharmaceutical Preparations stocks, PBH ranks #33 by Quality of Company score. CirclFi's QOC score of 8.1/10 evaluates 32 fundamental signals. A score of 8.1 places PBH in the top tier.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Prestige Consumer Healthcare In's positioning within the Pharmaceutical Preparations segment means that pipeline depth and stage distribution plays an outsized role in fundamental analysis. The sector's unique characteristics — including late-stage pipeline catalysts — shape both the opportunity set and risk profile.
Is PBH a Value Trap?
CirclFi's Value Trap algorithm assigns PBH a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Prestige Consumer Healthcare In. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Prestige Consumer Healthcare In scores 8.1 out of 10 on our 32-signal quality assessment, a strong rating that demonstrates strong fundamentals across the majority of our quality signals. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +179.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every PBH valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across PBH's 12 active models, average confidence is 55%. Moderate confidence indicates reasonable fit.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad